<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0229239.ref038">
 <label>38</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Asselah</surname>
   <given-names>T</given-names>
  </name>, 
  <name>
   <surname>Lee</surname>
   <given-names>SS</given-names>
  </name>, 
  <name>
   <surname>Yao</surname>
   <given-names>BB</given-names>
  </name>, 
  <name>
   <surname>Nguyen</surname>
   <given-names>T</given-names>
  </name>, 
  <name>
   <surname>Wong</surname>
   <given-names>F</given-names>
  </name>, 
  <name>
   <surname>Mahomed</surname>
   <given-names>A</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial</article-title>. 
  <source>Lancet Gastroenterol Hepatol</source>. 
  <year>2019</year>
  <month>1</month>;
  <volume>4</volume>(
  <issue>1</issue>):
  <fpage>45</fpage>â€“
  <lpage>51</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S2468-1253(18)30341-8</pub-id>
  <?supplied-pmid 30393106?>
  <pub-id pub-id-type="pmid">30393106</pub-id>
 </mixed-citation>
</ref>
